Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.24 USD | +1.92% | -13.47% | -9.79% |
11/06 | MaxCyte CEO Maher Masoud buys 100,000 shares | AN |
11/06 | Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing | MT |
Business Summary
Number of employees: 143
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell Therapy
55.3
%
| 31 | 69.0 % | 23 | 55.3 % | -25.26% |
Program-related
27.8
%
| 5 | 10.4 % | 11 | 27.8 % | +148.38% |
Drug Discovery
16.9
%
| 9 | 20.6 % | 7 | 16.9 % | -23.14% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 44 | 100.0 % | 41 | 100.0 % | -6.72% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Douglas Swirsky
DFI | Director of Finance/CFO | 54 | 27/23/27 |
James Brady
CTO | Chief Tech/Sci/R&D Officer | - | - |
Ron Holtz
ADM | Chief Administrative Officer | 66 | 01/05/01 |
Corporate Officer/Principal | - | 21/23/21 | |
Gene Zhu
LAW | General Counsel | - | - |
Jill Mayer
HRO | Human Resources Officer | - | 01/18/01 |
Thomas Ross
SAM | Sales & Marketing | 63 | 15/14/15 |
Steven Nardi
PRN | Corporate Officer/Principal | - | 13/20/13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Balthrop
BRD | Director/Board Member | 67 | 01/22/01 |
Art Mandell
BRD | Director/Board Member | 71 | 01/06/01 |
Will Brooke
BRD | Director/Board Member | 68 | 01/04/01 |
Stanley Erck
BRD | Director/Board Member | 76 | 01/05/01 |
Ron Holtz
ADM | Chief Administrative Officer | 66 | 01/05/01 |
John Johnston
BRD | Director/Board Member | 65 | 01/16/01 |
Richard Douglas
CHM | Chairman | 71 | 12/18/12 |
Yasir Al-Wakeel
BRD | Director/Board Member | 42 | 15/21/15 |
Rekha Hemrajani
BRD | Director/Board Member | 54 | 15/21/15 |
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 104,544,289 | 97,857,767 ( 93.60 %) | 0 | 93.60 % |
Company contact information
Sector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.37% | 22TCr | |
+10.21% | 19TCr | |
+28.22% | 15TCr | |
+34.42% | 11TCr | |
+0.80% | 6.32TCr | |
+19.21% | 5.48TCr | |
+0.13% | 4.85TCr | |
-4.16% | 3.89TCr | |
+2.39% | 3.61TCr |
- Stock Market
- Equities
- MXCT Stock
- MXCT Stock
- Company MaxCyte, Inc.